Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous hematopoietic stem cell infusion
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous hematopoietic stem cell infusion is a cellular therapy being investigated for the treatment of prolonged cytopenia, a common and potentially severe complication following Chimeric Antigen Receptor (CAR) T-cell therapy. Developed by the Institute of Hematology & Blood Diseases Hospital in China, this intervention involves the intravenous administration of a patient's own hematopoietic stem cells (HSCs) that were previously collected and cryopreserved. The goal of the therapy is to provide a "stem cell boost" to repopulate the bone marrow and restore multi-lineage hematopoiesis in patients whose blood counts have failed to recover after lymphodepleting chemotherapy and CAR-T cell infusion. This approach aims to mitigate the risks of infection and bleeding associated with persistent neutropenia and thrombocytopenia without the need for the intensive conditioning regimens typically required for full stem cell transplantation.
- Other names
- Autologous HSC infusionAutologous hematopoietic stem cellsAutologous stem cell boost
Beyond the preview
Go deeper on Autologous hematopoietic stem cell infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous hematopoietic stem cell infusion.